trea

  1. T

    Abnormality Discovered In Patients With Specific Ataxia That Could Be Target For Trea

    An abnormality discovered by U-M researchers in mice with Spinocerebellar Ataxia type 3 could represent a target for therapy. In a paper published this week in the Journal of Neuroscience, U-M researchers found that a particular dysfunction in neurons occurs well before the death of neurons...
  2. T

    Abbott Receives U.S. FDA Approval For RX Herculink Elite® Renal Stent System For Trea

    Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension...
  3. T

    FDA Provides 510k Clearance For BARRX Medical's HALO90 Ablation Catheter For The Trea

    BARRX Medical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its HALO90 Ablation Catheter for the treatment of Radiation Proctitis (RP) and Gastric Antral Vascular Ectasia (GAVE). Both conditions are diseases of the...
  4. T

    FDA Provides 510k Clearance For BARRX Medical's HALO90 Ablation Catheter For The Trea

    BARRX Medical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its HALO90 Ablation Catheter for the treatment of Radiation Proctitis (RP) and Gastric Antral Vascular Ectasia (GAVE). Both conditions are diseases of the...
  5. T

    FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Trea

    Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. More...
Back
Top